IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer (IFCSLAPC)
Primary Purpose
Pancreatic Cancer
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Concurrent chemoradiotherapy(CCRT)
Stereotactic Radiotherapy(SBRT)
S-1
Sponsored by
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring Pancreatic cancer, Intraoperative radiotherapy(IORT), Postoperative radiochemotherapy
Eligibility Criteria
Inclusion Criteria:
- Diagnosed as locally advanced pancreatic cancer.
- Cannot be treated by surgical resection.
Exclusion Criteria:
- Treated by chemotherapy or radiotherapy before.
- With distant organ metastasis.
- Cannot tolerate surgery (Intraoperative radiotherapy)
Sites / Locations
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Concurrent chemoradiotherapy(CCRT) Group
Stereotactic Radiotherapy(SBRT) Group
Arm Description
Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
Outcomes
Primary Outcome Measures
Overal survival
OS
Secondary Outcome Measures
Disease-specific survival
DSS
Progression-free survival
PFS
Local control rate
LCR
Full Information
NCT ID
NCT02734680
First Posted
April 7, 2016
Last Updated
April 9, 2017
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT02734680
Brief Title
IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer
Acronym
IFCSLAPC
Official Title
Intraoperative Radiotherapy(IORT) Followed by Concurrent Chemoradiotherapy(CCRT) or Stereotactic Radiotherapy(SBRT) for Locally Advanced Pancreatic Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Unknown status
Study Start Date
February 2016 (undefined)
Primary Completion Date
February 2018 (Anticipated)
Study Completion Date
February 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to find the best model of combination of intraoperative radiotherapy(IORT) and postoperative radiochemotherapy for pancreatic cancer.
Detailed Description
The trial is funded by Cancer Foundation of China. The trial is prepared to be registered on the clinicaltrail.gov.
Quality assurance plan: every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences.
Data check: the investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.
Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.
Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant.
Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.
Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 70 participants to take part in the trail. The investigators can recruit about 35 participants every year according to previous experiences, so the investigators should recruit at least for two years.
Plan for missing data: the investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results.
Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P < 0.05.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Cancer
Keywords
Pancreatic cancer, Intraoperative radiotherapy(IORT), Postoperative radiochemotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Concurrent chemoradiotherapy(CCRT) Group
Arm Type
Experimental
Arm Description
Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
Arm Title
Stereotactic Radiotherapy(SBRT) Group
Arm Type
Experimental
Arm Description
Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
Intervention Type
Radiation
Intervention Name(s)
Concurrent chemoradiotherapy(CCRT)
Other Intervention Name(s)
Concurrent chemoradiotherapy
Intervention Description
Radiation and take gemcitabine(GEM)
Intervention Type
Radiation
Intervention Name(s)
Stereotactic Radiotherapy(SBRT)
Other Intervention Name(s)
Stereotactic Radiotherapy
Intervention Description
Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
Intervention Type
Drug
Intervention Name(s)
S-1
Other Intervention Name(s)
S-1 orally
Intervention Description
Taking S-1 orally after radiation
Primary Outcome Measure Information:
Title
Overal survival
Description
OS
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Disease-specific survival
Description
DSS
Time Frame
2 years
Title
Progression-free survival
Description
PFS
Time Frame
2 years
Title
Local control rate
Description
LCR
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed as locally advanced pancreatic cancer.
Cannot be treated by surgical resection.
Exclusion Criteria:
Treated by chemotherapy or radiotherapy before.
With distant organ metastasis.
Cannot tolerate surgery (Intraoperative radiotherapy)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yingtai Chen, PhD
Phone
+8618600258827
Email
yingtai.chen@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Shuisheng Zhang, M.D.
Phone
+8618001302322
Email
thelifeofwater@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chengfeng Wang, B.A.
Organizational Affiliation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yingtai Chen, PhD
Phone
+8618600258827
Email
yingtai.chen@hotmail.com
First Name & Middle Initial & Last Name & Degree
Shuisheng Zhang, M.D
Phone
+18001302322
Email
thelifeofwater@126.com
First Name & Middle Initial & Last Name & Degree
Chengfeng Wang, B.A.
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer
We'll reach out to this number within 24 hrs